Patents by Inventor Cornelia Heinz

Cornelia Heinz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20240091312
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: August 24, 2023
    Publication date: March 21, 2024
    Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Wöll, Stefan Jacobs, Cornelia Heinz
  • Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma
    Patent number: 11826402
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: November 28, 2023
    Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitatsm
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
    Patent number: 10946069
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: March 16, 2021
    Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20210023177
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: October 8, 2020
    Publication date: January 28, 2021
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20190298803
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: May 2, 2019
    Publication date: October 3, 2019
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
    Patent number: 10314890
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 11, 2019
    Assignees: ASTELLAS PHARMA INC., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20180000900
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: August 23, 2017
    Publication date: January 4, 2018
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma
    Patent number: 9770487
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: September 26, 2017
    Assignees: Ganymed Pharmaceuticals AG, TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gGmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20150374789
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: February 18, 2014
    Publication date: December 31, 2015
    Applicants: GANYMED PHARMACEUTICALS AG, TRON-Translationale Onkologie an der Universitats- medizin der Johannes Gutenberg-Universitat Mainz.
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz